A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC
Status:
Completed
Trial end date:
2019-09-17
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of the combination of
necitumumab with pembrolizumab in participants with stage IV non-small cell lung cancer
(NSCLC).